Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Mendus, Audiocast with teleconference, Q1'24

By Inderes5/17/2024, 12:00 PM
Mendus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:01 - 16:13

Good afternoon everyone. Thanks for participating in the Q1 report of 2024. As a company, please pay attention to our disclaimer. And to start with Q1. We made significant progress and we were proud to present that progress together with our business partners, ALLG and NorthX Biologics. ALLG is our Australian partner, the Australasian Leukaemia & Lymphoma Group, with whom we are involved in the AML 22 cadence trial. And NorthX Biologics is a manufacturing organization based here in Sweden, who are our partner for large scale manufacturing of early productivity data. We also received in the first quarter Ethics committee approval to allow for the start of the AML 22 cadence trial, which is currently ongoing. And we have progress in our NK cell program, which we presented at the Innate Killer Summit, which is a leading conference on that specific topic of cell therapies. We were very happy to announce that our major shareholders, as well as management and board members, announced their intention to execute the warrants that we issued as part of last year's financing. And in the end, we raised roughly 69 million Swedish kronor through the exercises of warrants and that provides us with cash runway until the third quarter of 2025, based on our currently planned activities. Residential. We've taken initial steps towards late-stage development. We reported at the end of last year, very positive data about the NK cell program in acute myeloid leukemia. And the data showed promising survival results and at the same time also brought together a lot of the immuno monitoring data we collected as part of the trial. And those immuno monitoring data not only supported the mechanism of action of our products as an immunotherapy that stimulates the immune system to act against residual cancer cells, it was also clearly associated with the clinical benefit we observed in the clinic. So we were very happy with those data which we presented at the ASH conference at the end of last year. Then, together with ALLG, the Australasian Leukemia and Lymphoma Group, we have prepared a trial with oral azacitidine, which is the current standard of care in AML maintenance. And we were awaiting ethics committee approval, which in the end we got in March and allowed us to start the trial. The registration trial, which we are planning to do. The AML trial is one that we are separately preparing for. The company-sponsored trial. The trial is actually run by ALLG in collaboration with us. But the registration trial is a trial that you have to prepare for as a company-sponsored trial. That is a parallel track, and we are very much encouraged by the initial positive feedback we received from the FDA on the steps we have planned towards that path. Also importantly, the manufacturing alliance with NorthX Biologics is on track. So we started that collaboration after the summer last year. And now in the meantime, we have established a production facility which is ready, and also the tech transfer process has started. So we've done the initial training run, including the filling of vials, in the first quarter of this year. And now we are continuing with the tech transfer process, and we anticipate being able to deliver the first GMP batches of our cell-based product based on this large scale production process in mid-2025, which will also put us in a position, together with the trial preparations, to be ready for a pivotal stage trial. About the other pipeline programs. We have an ongoing phase one trial in ovarian cancer. It is pursuing the same principle. We are pursuing an AML maintenance treatment, which is applied after initial treatment when the tumor burden is relatively low. We try to boost the immune system against residual cancer cells. In this case, it's ovarian cancer patients who have undergone high-dose chemotherapy in combination with surgery. And then we provide our vaccination scheme of six vaccinations. A fixed cell and the primary endpoints of the trial are safety and immunogenicity in this indication. And we have already reported initial positive data. We will also report in 2024 on the trial, including a primary readout in 2024. In the second half, our second clinical stage product is Ilixadencel. We have been preparing this product to re-enter the clinic after we redesigned the manufacturing process, and we are still pursuing that route. It has faced delays. We were initially planning to enter final negotiations around the end of last year's trial but had to shift our focus towards another group of clinical centers and potential partners, and this process is currently ongoing. We are pursuing the program and are aiming to conclude the discussions I just described in the first half of 2024. And then finally we have a preclinical and clinical program, which we think is very promising because it is based on the expansion of so-called memory NK cells, which are strongly associated with clinical benefits in different tumor settings. And so this is a program that could, in the future, become a new pipeline program based on our in-house research. Ilixadencel is positioned as a maintenance therapy. And what is special about maintenance therapy is that it allows patients to stay in a disease-free state longer after initial treatment, and this is addressing one of the major challenges in cancer therapy today. So initial therapies, including chemotherapy that address the initial tumor, are generally successful. But the most deadly tumors, including acute myeloid leukemia or AML, are so deadly because they come back very quickly after initial treatment. Another reason to address low-disease settings is the fact that our cell therapy is an active immunotherapy. It means that it trains the immune system of the patient to build up long-lasting immunity over residual cancer cells, and that active immunity, which can only build up through the disease itself or via vaccination, just takes time to build up, usually a couple of weeks. But we're also seeing in our own Phase 2 trial that 2 to 4 weeks in the first set of vaccinations is enough to start building up the immunity. But it does take some time, and the immune system has to be in good shape to be able to mount an immune response. And this is building up to the concept depicted here, where we try to build up active immunity against residual cancer cells, resulting in long-term relapse-free and overall survival for patients. But it also has a competitive product profile. It is a cell line-based product, which means we can effectively scale up manufacturing, which we are currently, of course, carrying out together with NorthX Biologics. The nature of the product is so-called off-the-shelf. So we can make large quantities of the product, store the product frozen, and it's ready to be shipped to hospitals on demand. Also, it's a relatively straightforward product. It can be stored at bedside and injected into the patient. The only side effects we have seen are actually redness in the skin where we administer the product, which also supports the mode of action of the product as a vaccine. We have a strong regulatory dossier, including a GMP certificate from the European authorities around our manufacturing process, orphan drug designation in the US and Europe, and a fast track designation, which we obtained at the end of last year in the US. AML is a devastating disease and is still largely an unresolved disease. The five-year survival rate has remained largely unchanged and is only 30%. The main reason is that unless patients undergo a bone marrow transplant, the disease unavoidably comes back, and disease relapse remains the major barrier to long-term survival in adult AML. Another important element about maintenance therapies is that they have to be safe. And that is one of the elements that we feel makes vididencel competitive. A very competitive approach is the combination of ilixadencel and vididencel. Training active immunity results in long-lasting control of the disease, but also a product with a safety profile that is compatible with the maintenance setting. The current standard of care for AML maintenance is oral azacitidine. This is one of the data points from the registration trial of oral azacitidine. And what you can clearly appreciate is that the blue line, which represents the placebo, shows that patients with measurable residual disease after their initial chemotherapy relapse very quickly. Actually, the majority of patients relapse already within the first three months with oral azacitidine, which is a small molecule chemical drug in tablet form. You see that this curve shifts and the median relapse-free survival is seven months. But it's still a very disappointing picture, with the vast majority of patients relapsing and soon afterwards passing away very quickly. So there is a lot of room to improve on the current standard of care. What we have done is, after a successful Phase 1, which showed that patients with a low disease burden had a chance of long-term durable remissions. Following treatment with vididencel, we started the Phase 2 trial, which is the currently ongoing advanced two trial. And this trial was comprised of six vaccinations of vididencel in patients who had successfully undergone initial chemotherapy. So they were in the first complete remission, but still diagnosed with measurable residual disease, putting them at a higher risk of relapse. This is the data we presented at the end of last year at ASH. And what you will appreciate is that after an initial group of patients relapsing and then also passing away relatively quickly, there was a remarkably large group of patients, being 14 out of 20, that was alive at the end of the active trial phase, which was a 70-week trial phase. And the great news we could report at the end of last year at ASH is that those 14 patients were still alive at the end of last year. We are currently with the majority of patients alive. We are not at the point where we can determine an overall survival median. We do have a median relapse-free survival. At the last readout, it was two and a half years. The most important part of this set of data is that you start to see durable remissions and durable overall survival in acute myeloid leukemia following treatment with vididencel. Another important set of data we reported last year is called immune monitoring data, whereby we study the immune system of patients. And first of all, this led to a much deeper understanding of how the immune system responds to the cell. But also, very importantly, we saw that these immune responses correlated with the clinical benefit. And this is a kind of data that we continue to collect and also continue to report on, including this week at the Simp conference. And this basically documents the immune responses, not only on the level of T cells against specific tumor antigens but also other parts of the immune system such as B cells and dendritic cells. And also we saw that, for example, suppressive immune cells were affected by the cell treatment, leading to lower levels of suppressive cells and increased levels of activated cells. Also, what was clear is that the patients who relapsed unfortunately had a very poor immune system and were hardly able to build up immune responses. So that also explains why a subgroup of patients did not respond. Currently we are addressing patients after high-dose chemo. So the chemo fits the patient population. Uh, and since oral azacitidine is now the approved drug, that is the first, uh, next step we will take. And we are doing this as we speak, uh, in collaboration with ALLG and NorthX Biologics in M22 cadence trial. This is also the initial patient population that we will prepare a registration trial for. It is clear that other AML patients will benefit from this treatment. And that is why we also consider to explore additional patient populations, including patients who have undergone a bone marrow transplant but are still at a high risk of relapse if they are still MRD positive, but also a new group of patients which is treated with a new drug called 2 clicks uh, leading to more patients in complete remission in a group of patients that was recently deemed chemo unfit, but with much higher remission rates That also creates a patient population that will benefit from maintenance therapy. So the M22 cadence trial, as I said, is now starting with ethics committee approval. Out of the way. Uh, we have shipped material to Australia. We're starting up the clinical sites. Uh, the first phase of the trial will comprise 40 patients, uh, equally divided over associated and alone or associated with vididencel and ilixadencel. And then assuming no safety issues. And the trial will continue to recruit another 100 patients. So this is a very significant trial in terms of data. We expect it will generate confidence in combination with oral azacitidine. And we're extremely happy to do it with ALLG, which is one of the leading research groups in this field worldwide, with Andrew Wei as the lead investigator. So how does it add up to our, uh, strategy for the clinical pipeline? I said the advance to monotherapy trial is still in long-term follow-up. So we will continue to monitor the, um, the progress of that trial. The AML M22 cadence trial is starting and will generate initial data in 2025. And particularly those data will reflect the initial safety, uh, which we can see in that first patient group treated in parallel. Uh, we are preparing for a global registration trial. And that preparation phase will comprise two parts. It's on the one hand coming to a trial design and also, uh, interactions with the regulatory authorities that will allow us to, uh, to come to a trial design that is also seen as the right one by the, by the regulators. We are in regular interactions with both the FDA and EMA. So this part is the preparation phase we will do in-house. Then the other part is the manufacturing. And that is the project we are currently carrying out with NorthX Biologics. Again, the facility is up and running. The preparation phase has been concluded, and we are now in the so-called tech transfer phase, which will take us into 2025 and which will release the first large scale GMP batches, hopefully mid next year. So with that, I will come to the summary and outlook for 2024 based on the positive data in the Phase 2 trial. We are moving forward to late stage development of vididencel in AML. We have Ethics Committee approval allowing for the start of the AML 2022 cadence trial in collaboration with ALLG. We are, as part of the late stage development strategy, building up a global network of clinical centers. We had already worked with ten clinical centers in Europe. For the Phase 2 trial. We have opened the IND in the US, allowing us to start trial activities in the US. And now also with ALLG, we're opening up a much broader network of clinical centers in Australia and New Zealand and a number of Asian countries. So an important addition to our global clinical trial network, the manufacturing alliance with NorthX Biologics, is on track for large scale manufacturing of the cell, for the clinical trial, the registration trial. But in the end also for commercial launch. And we are preparing for pivotal stage readiness, based on the trial preparations and large scale GMP manufacturing expected to be ready in 2025. Second half all the developments are supported by a strong regulatory dossier around the cell. And then for the other programs, we expect additional readouts from the ilixadencel Phase 1 trial in ovarian cancer, including the primary analysis in the second half of this year. And we continue to pursue ilixadencel as a program, which we want to bring back into the clinic in soft tissue sarcomas. With that, it's the end of my presentation and we're open for Q&A.

Operator
16:17 - 16:37

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Chen Hun Lee from Perito Securities. Please go ahead.

Unknown 2
16:41 - 17:01

Hi. Good afternoon. So a few questions from me. Could you elaborate a bit on the timeline of the cadence trials, and how would the data be used in registration and trial? Would that be mainly safety data next year? And does the pivotal trial need to wait for the readouts for cadence? Thank you.

Unknown 3
17:02 - 17:02

Sure.

Unknown 1
17:03 - 17:32

Thanks for joining us, Chen. The long story short is, uh. Yes, we are expecting some initial safety data from the trial, and that will of course support the preparations for a Phase 3 registration. But it's not so that we are dependent on the data from the cadence trial to start such a registration trial, but they will support the global registration dossier. I'll show you, uh, if you want to add in that statement.

Unknown 4
17:34 - 17:43

I think we are planning to set up the randomized Phase 3 trial and the cadence trial. Uh, does not interfere with those timelines.

Unknown 2
17:45 - 17:59

Okay. Thank you. Maybe a follow-up question. So for the registration trial, do you think you would need the same amount of patients as in the registration trial for overall authorization? Or can you potentially lower the patient number?

Unknown 4
18:01 - 18:28

Yeah, I think it's difficult to comment now on exact patient numbers, but, uh, yeah, if you look at, say, the data as you refer to, I think these are foreseeable sample sizes, but it all depends on the effect size. And uh, I think when we are more advanced, uh, after the interactions also with regulators, we will be able to disclose more details on a potential registration trial.

Unknown 2
18:31 - 18:33

Okay. Got it. Uh, thanks for taking my question.

Unknown 3
18:34 - 18:35

Thanks, John.

Operator
18:39 - 18:44

The next question comes from Sir Ramana from Edison Group. Please go ahead.

Unknown 5
18:49 - 19:09

Uh, thank you for taking my question. Uh, you know, just to follow on from Watkins, uh, for the cadence combination trial. Uh, I think we have some data for evidence on the monotherapy in MRD negative patients. Do you think regulators will want to see this data in the later stages of clinical development?

Unknown 1
19:12 - 19:18

Sorry. So can you, uh, maybe we can clarify the question as well. So about MRD negative patients. Correct?

Unknown 5
19:19 - 19:27

Yes, yes. So do you think that the regulators will want to see this data in the later stages of the clinical development?

Unknown 1
19:28 - 20:22

Well, I think, just high level, It would go into how exactly we plan for our registration trial. So it would be too detailed to comment on that now. But your observation that the cadence trial also includes MRD negative patients is correct. And the reason is, uh, that, uh, MRD assessments are such that there's no false positive MRD. Right. So when you pick up MRD it is there, but there are false negative MRD. Also in the MRD negative patient population, relapse rates and overall survival are still disappointingly low, particularly in patients that cannot be transplanted. So your observation that the Cadence trial indeed allows us to explore both patient populations, which we see as a positive because it will generate a lot more additional data. Uh, that is correct whether or not we incorporate that in our late-stage registration trial, that is still to be decided and to be disclosed.

Unknown 5
20:24 - 20:46

Yeah. And also for, uh, vididencel. And so I think in AML, we're looking forward to the update for the ovarian cancer program. I assume that, um, do you intend to move directly into Phase 2 or do you think you'll need to prioritize, um, for other indications?

Unknown 1
20:47 - 22:12

Right? Well, I think it's a matter of means and focus. Uh, so when we started this exercise to see if Ilixadencel would be a potential treatment for low disease settings, we cast out the net quite wide, right, which was in AML, which is a very aggressive disease in terms of relapse rates and ovarian cancer, which is also aggressive but somewhat slower disease as compared to AML. What we are seeing consistently is robust immune responses in both patient populations. And the primary readout of the ovarian cancer trial is actually safety and immunogenicity. So we have already indicated that those data start to look very positive, whether or not we will see a strong enough clinical effect and also will have, let's say, enough breadth as a company, uh, in terms of means that we can put behind different trials and to pursue them. That's obviously still something we need to consider once we have, uh, a more, let's say, mature data set from that trial. Uh, but we are always taking data-driven decisions, right? So it starts with the fact whether or not we see enough promise in the data to take the program forward, and then we have to balance it with the additional opportunities. And the additional opportunities are not only, let's say, in solid tumor indications for both Ilixadencel and vididencel, but clearly also we see now the potential of the product to be broadly positioned in the oncology space. So that's a more broader strategic question which we are currently actively thinking about obviously.

Unknown 5
22:14 - 22:31

Okay. And my last question is really, um, thank you for that. My last question is really more of housekeeping. The R&D was a lot higher than I thought it was going to be in the quarter, which kind of makes sense because there's been a lot of activity. What do you think the run rate is going to be going forward?

Unknown 1
22:32 - 22:50

Well, the simple answer there too is we are starting up the Cadence trial, right? So you will start to see that back in our R&D costs. And with respect to the Cash Runway, we can just repeat what we stated, which is we have cash runway based on currently planned activities. So that includes also the start of the Cadence trial until Q3 2025.

Unknown 5
22:51 - 22:52

Okay. Thank you so much.

Unknown 3
22:53 - 22:53

Thanks, sir.

Operator
22:58 - 23:04

The next question comes from an attendee from India. Please go ahead.

Unknown 6
23:06 - 23:28

Good afternoon, and thank you for taking my questions. Some of them were already covered, but I just wanted to ask a practical question on the CADENCE trial. Uh, do you have any estimate or a reasonable timeframe on when the first 40 patients will be recruited, and also when will be the first readout of the cadence trial?

Unknown 1
23:29 - 24:52

Yes, I think there are two parts to that question. Thanks for joining us. The first part is that we are starting off the trial as we speak, which means the material has safely arrived in Australia. Luckily, but also, of course, we're starting up the clinical centers and there's always a kind of hockey stick in the recruitment rate of a trial. Right. So, the first and most important part, and that was what we were aiming for when we did the last business update, was to make sure we have Ethics Committee approval. Right now, we are starting up the trial. It's ALLG who's running the trial. As a company, we will not make very specific comments about individual patients being recruited or patient numbers. But we will, together with ALLG, look at regular intervals with which we can, uh, monitor the trial, the most important readout we see. And this will also be, to a large extent, the initial benefit we see from the Cadence trial is the safety data in combination with efficacy. And we have limited data with SSI today, and from Phase 1, but not in such a structured and randomized controlled way as we are now seeing from the Cadence trial. So that is, first and foremost, what we're focused on. And that data will come in the course of next year. I think, much more important is the second stage of the cadence trial, which will, of course, with larger patient numbers, allow us to evaluate the combination in terms of clinical benefits.

Unknown 6
24:54 - 24:57

Okay. That's all from me for now.

Unknown 3
24:57 - 24:58

Thanks.

Operator
25:02 - 25:06

The next question comes from Christian Binder from Redeye.

Unknown 7
25:11 - 25:36

Hi, and thanks so much for taking my question. I just have one follow-up. Regarding the registration trials, you already mentioned that you can't elaborate too much right now, but, if possible, when it comes to trial design compared to the second part of cadence for registration and trial, are there any other key trial design differences that we should expect?

Unknown 4
25:40 - 26:19

Well, I think, like I said, Christian. We can disclose those details once we have had the interactions. Also, we're coordinating with the authorities because it would be premature to comment on it otherwise. But I think one of the things we could, of course, indicate is that there is the possibility for us to maybe focus on those patients with the highest need, which could be, say, patients who are clearly positive, as we already selected within the advanced study. So that could be one of these considerations, from a design perspective, to focus on those patients in highest need to show the benefit that we currently see in advance too.

Unknown 7
26:22 - 26:24

All right. Thank you so much.

Unknown 3
26:25 - 26:25

Thanks, Crystal.

Operator
26:28 - 26:34

The next question comes from Nils Andersson from Private Investor. Please go ahead.

Unknown 3
26:40 - 26:40

Hello.

Unknown 4
26:41 - 26:44

I have a question regarding the study.

Unknown 3
26:44 - 27:20

Study, and you partially answered it earlier in the presentation. But I would like you to elaborate on the answer a little bit. Uh, in mid-November last year, you announced to the market that the study would start within six weeks. And I guess that by that time, preparations must have been very advanced and all sites must have been contracted, as the study was expected to start in only six weeks. Now, six months have passed since then and the study still hasn't started. So can you comment on what happened from mid-November to the end of December?

Unknown 1
27:21 - 28:17

Right. Just we put everything in place. Uh, Nils, thanks for joining, by the way, and asking your question to be able to have a trial ready by the year end and, uh, yeah, in the, in the, let's say, discussions with partners we were involved in at the time, uh, things changed to the extent that we decided to change course and that related to both, uh, the discussions we were having, uh, but also more specifically, uh, just as an indication was a relatively narrow indication with a relatively large amount of competition. So we have shifted now to the broader soft tissue sarcoma indication. But also we had to find a new possibility to do that trial. And that is the, uh, events that, uh, came together, let's say, end of last year. Uh, and that's also why we are now still pursuing that option, but in a different setting, uh, as compared to where we were at the end of last year. That's as much as I can say about it.

Unknown 3
28:19 - 28:21

Okay. Thank you very much. Thanks.

Operator
28:29 - 28:36

There are no more questions at this time, so I hand the conference back to the speaker for any written questions and closing comments.

Unknown 1
28:37 - 28:58

Thanks so much. Also, thanks for, uh, everybody joining online. Uh, who did not ask questions. Uh, I think most of the questions that we received today are aligned with what we also saw coming in via the email address. So I think all of the main questions have been answered. So back to the operator. And uh, have a great weekend, everybody.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…